CME (CME) Q4 2024 Earnings Call Transcript

CME Group reported record 2024 results, with revenue up 10% to $6.1 billion, adjusted net income up to $3.7 billion, and average daily volume rising 9% to 26.9 million contracts. Management guided 2025 adjusted operating expenses to about $1.65 billion, capex to $90 million, and said recent fee changes plus the collateral surcharge could lift pre-tax income by 2% to 2.5%. The company also highlighted strong commodities momentum, record international volume, a $3 billion repurchase authorization, and continued crypto, BrokerTec, and clearing expansion efforts.

Analysis

The core read-through is that CME is quietly converting cyclical volume strength into a higher-quality, more durable earnings stream: pricing, data, and collateral monetization are becoming more important than pure contract growth. That matters because it reduces sensitivity to “volumes normalize” fears and makes the equity more bond-like in a good way — a self-funding cash compounder with embedded operating leverage and limited capex needs. The market may be underestimating how much of the 2025 uplift is already visible in the first quarter through pricing actions and a change in customer collateral behavior, which creates an earnings bridge before any additional volume upside shows up.

The second-order winner is not just CME, but any brokerage, clearing, and execution platform that benefits from rising derivatives adoption by retail and multi-strat funds. The flip side is pressure on smaller futures venues and OTC alternatives: as more client workflows migrate into standardized listed products, liquidity concentrates where the ecosystem is deepest, which should reinforce CME’s moat rather than erode it. Crypto expansion is the optionality piece, but the bigger strategic call is that the company is building infrastructure for a broader “risk management rail” spanning commodities, rates, and data — a setup that can outlast any one macro regime.

The main risk is valuation and political/regulatory overhang, not near-term demand. If volatility compresses faster than expected, the market could de-rate the multiple before earnings revisions catch up; likewise, any pushback on fee increases or collateral policy could mute the upside by a quarter or two. But the more interesting contrarian is that rising insurance, weather, and tariff uncertainty may be a structural demand driver for years, meaning the current cycle could be the early innings of a long-duration volume expansion rather than a peak.

Key Decisions for Investors

• Long CME common into the next 1-2 quarters on pullbacks: the setup is favorable for estimate revisions from pricing, market data, and collateral mix, with downside cushioned by capital returns and low capex.
• Pair trade: long CME / short exchange operator basket with heavier equity/IPO sensitivity (e.g., ICE/other market infrastructure peers if available in portfolio) to isolate the higher-quality recurring revenue and clearer 2025 earnings bridge.
• Buy CME 6-12 month call spreads financed with short-dated upside sales: best risk/reward if volumes stay firm and fee actions stick, while limiting valuation risk if the multiple compresses.
• Relative-value long CME vs. rate-sensitive brokers/clearing names over 3-6 months: CME is less dependent on underwriting or capital markets recovery and more exposed to persistent volatility and hedging demand.
• Avoid chasing after a big volume print; use any post-earnings or macro-driven selloff to add, since the real upside comes from fee/mix leverage rather than a one-quarter spike in contracts.